Research Article

Identification of Candidate Therapeutic Target Genes and Profiling of Tumor-Infiltrating Immune Cells in Pancreatic Cancer via Integrated Transcriptomic Analysis

Wei Ding, Yuxu Wang, Yongbiao Ma, Li Lin, and Manjiang Li

Department of Hepatobiliary & Pancreatic Surgery, Weifang People’s Hospital, No. 151 of Guangwen Street, Weifang, 261041 Shandong Province, China

Correspondence should be addressed to Manjiang Li; 1015670212@qq.com

Received 20 June 2022; Revised 2 August 2022; Accepted 10 August 2022; Published 23 August 2022

Pancreatic cancer (PC) has a dismal prognosis despite advancing scientific and technological knowledge. The exploration of novel genes is critical to improving current therapeutic measures. This research is aimed at selecting hub genes that can act as candidate therapeutic target genes and as prognostic biomarkers in PC. Gene expression profiles of datasets GSE101448, GSE15471, and GSE62452 were extracted from the GEO database. The "limma" package was performed to select differentially expressed genes (DEGs) between PC and normal tissue samples in each dataset. Robust rank aggregation (RRA) algorithm was conducted to integrate multiple expression profiles and identify robust DEGs. GO analysis and KEGG analysis were conducted to identify the functional correlation of the DEGs. The CIBERSORT algorithm was conducted to estimate the immune cell composition of each tissue sample. STRING and Cytoscape were used to establish the protein-protein interaction (PPI) network. The cytoHubba plugin in Cytoscape was performed to identify hub genes. Survival analysis based on hub gene expression was performed with clinical information from TCGA database. 566 robust DEGs (338 upregulated genes and 226 downregulated genes) were identified. Tumor tissue had a higher infiltration of resting dendritic cells and tumor-associated macrophages (TAM), including M0, M1, and M2 macrophages, while infiltration levels of B memory cells, plasma cells, T cells CD8, T follicular helper cells, and NK cells in normal tissue were relatively higher. GO terms and KEGG pathway analysis results revealed enrichment in tumor-associated pathways, including the extracellular matrix organization, cell–substrate adhesion cytokine–cytokine receptor interaction, calcium signaling pathway, and glycine, serine, and threonine metabolism, to name a few. Finally, FN1, MSLN, PLAU, and VCAN were selected as hub genes. High expression of FN1, MSLN, PLAU, and VCAN in PC significantly correlated with poor prognosis. Integrated transcriptomic analysis was used to provide new insights into PC pathogenesis. FN1, MSLN, PLAU, and VCAN may be considered as novel biomarkers of PC.

1. Introduction

PC is one of the deadliest malignant tumors. The global incidence of PC in 2020 was 495,773, with 466,003 reported deaths [1]. Current treatment methods for PC mainly emphasize surgery, chemotherapy [2], radiotherapy, and immunotherapy. Although surgical resection is considered potentially curative, most pancreatic cancers are difficult to diagnose in the early stages. Reports suggest that only 15% to 20% of PC patients are suitable for surgical resection, and most patients relapse within one year after surgery [3]. Notwithstanding that advancements in medical technologies have improved the ability of clinicians to detect, diagnose, and treat, a 5-year survival rate of 8% [4] has been reported, emphasizing the need to improve patient prognosis. Therefore, to improve the current management of PC, it is paramount to find new therapeutic targets and new prognostic biomarkers.

With extensive developments made in computer science and bioinformatics analysis, public databases including GEO and TCGA database have been increasingly used for enrichment analysis and identification of DEGs between tumor and normal tissue. A study by Deng et al. found 12 genes
2. Methods

2.1. Data Collection and Data Processing. Three RNA-sequence files of PC were extracted from the GEO database (https://www.ncbi.nlm.nih.gov/geo/), including GSE101448 (18 tumor and 13 nontumor tissue samples), GSE15471 (36 tumor and 36 nontumor tissue samples), and GSE62452 (69 tumor and 61 nontumor tissue samples) based on the following criteria: (1) entry type, (2) gene array sequence files and corresponding platform annotation files of each dataset. The selection criterion was set as \[ \left| \log_2 \text{fold change} \right| > 1 \] and adjusted \( p < 0.05 \) were considered as significant DEGs.

2.2. Identification of Robust DEGs. Before RRA analysis, each dataset’s upregulated and downregulated genes were ranked according to the logFC value. The “robust rank aggregation” R package merged DEGs from three datasets to obtain robust DEGs. Genes with \[ \left| \log_2 \text{fold change} \right| > 1 \] and \( p < 0.05 \) were considered as robust DEGs. A higher-ranked gene was associated with a smaller \( p \) value.

2.3. Functional Enrichment Analysis. To identify the functional roles of the robust DEGs indicated above, GO enrichment results of BP, CC, and MF were obtained using the R package “clusterProfiler.” The KEGG pathway analysis of robust DEGs was also conducted using the R package. \( p < 0.05 \) was considered to be statistically significant.

2.4. Immune Cell Infiltration. We used the CIBERSORT algorithm to calculate the immune composition of each tissue sample [10], with the cutoff criteria of \( p < 0.05 \).

2.5. Creation of PPI Network and Module Analysis. The PPI network of robust DEGs was created with the following method. First, the robust DEGs were uploaded to STRING [11]. Then, protein interactions with a confidence score > 0.7 were extracted from STRING and disconnected nodes were hidden from the network. The visualization of the PPI network was conducted by Cytoscape software [12]. The CytoHubba plugin MCODE was performed to select the meaningful modules from the PPI network.

2.6. Hub Gene Identification. To explore and screen hub genes from the PPI network, we used CytoScape. The CytoHubba plugin cytoHubba can perform operations on several topological analysis algorithms. Hub genes were identified from these algorithms [13].

2.7. The Relationship between Hub Genes and Prognosis. The RNA sequence and clinical data of 178 PC samples and 4 healthy samples were extracted from TCGA database (https://portal.gdc.cancer.gov/). “Survival” and “survminer” packages were performed to explore prognosis of PC patients. The visualization of K-M plot was performed via the K-M method.

3. Results

3.1. DEG Screening. Figure 1 displays the study workflow. We used the “limma” software package of R to select for DEGs in each dataset. The selection criterion was set as \[ \left| \log_2 \text{fold change} \right| > 1 \] and adjusted \( p < 0.05 \). In dataset GSE101448, a total of 1700 genes were significantly expressed, including 903 upregulated and 797 downregulated genes. In dataset GSE15471, a total of 919 genes were significantly expressed, including 174 upregulated and 745 downregulated genes. In dataset GSE62452, a total of 285 genes were significantly expressed, including 170 upregulated and 111 downregulated genes. Next, we used the RRA method to merge DEGs from 3 datasets. Finally, robust DEGs consisting of 338 upregulated and 226 downregulated genes were identified (Supplementary Table S1). Heat maps were generated to visualize the distribution of different genes in each dataset, and a heat map was generated to visualize the top 20 upregulated and downregulated robust DEGs (Figures 2(a)–2(d)).

3.2. GO and KEGG Analysis. GO enrichment analysis is used to annotate the degree of gene function terms in DEGs, which include BP, CC, and MF. The top 10 GO terms are displayed in Figures 3(a)–3(d).
GO annotation for BP included the extracellular structure and matrix organization, cell-substrate adhesion, and negative regulation of endopeptidase and peptidase activity; the CC consisted of collagen-containing extracellular matrix, endoplasmic reticulum lumen, apical part of cell, apical plasma membrane, and extracellular matrix component, while the MF involved the extracellular matrix structural constituent, glycosaminoglycan binding, serine-type peptidase activity, serine hydrolase activity, and endopeptidase regulator activity (Supplementary Table S2). GO enrichment analysis thus revealed that the robust genes were mainly related to the extracellular matrix (ECM) and could play a vital function in tumorigenesis.

KEGG pathway analysis (Supplementary Table S3) showed significant enrichment in the following pathways: cytokine-cytokine receptor interaction, calcium signaling pathway, glycerol, serine, and threonine metabolism, cytochrome P450 (Figures 3(e)–3(h)). The enrichment analysis revealed that the robust genes were mainly related to the extracellular matrix (ECM) and change of metabolic-related pathway, which could play a vital function in tumorigenesis.

3.3. Immune Cell Infiltration. We use the CIBERSORT method to predict the infiltration of immune cells, as shown in Figure 4(a). As seen from the visualized heat map, compared with normal tissues, tumor tissue had a higher infiltration of resting dendritic cells and TAM (including M0, M1, and M2 macrophages). Interestingly, in normal tissue samples, B memory cells, plasma cells, CD8 T cells, T follicular helper cells, and NK cells were relatively high (Figures 4(b) and 4(c)).

3.4. PPI Network Creation and Module Analysis. We made the PPI network of a total of 345 nodes, and 1082 protein pairs were obtained with a combined score > 0.7 (Figure 5(a)). In total, one module with score > 15 was selected by MCODE, of which the largest connected master network contains 30 nodes and 224 edges including 28 upregulated and 2 downregulated genes (Figure 5(b)).

3.5. Core Gene Selection. cytoHubba, a plugin of Cytoscape, exerts different topological methods, such as maximum neighborhood component (MNC), degree, edge percolated component (EPC), and centralities such as bottleneck, eccentricity, closeness, and radiality, which can be used to calculate the gene score of PPI network and rank the top 50 genes. According to the gene score, the top ranked genes can be considered as the hub genes. The intersection of these 50 genes from the 7 algorithms revealed the 4 hub genes: fibronectin 1 (FN1), mesothelin (MSLN), plasminogen activator, urokinase (PLAU), and versican (VCAN) (Figure 5(c)).

3.6. Survival Analysis. To determine the relationship between hub gene and prognosis, we conducted survival analysis using “survival” of R with clinical information from TCGA database. The optimal cutoff of each gene was determined using the surv_cutpoint function of the survminer package in R. The hub genes were allotted into high and low expression groups based on their respective optimal cutoff values: VCAN (5416), PLAU (1808), MSLN (429), and FN1 (31190). High expression of VCAN (p = 0.002), PLAU (p < 0.001), MSLN (p < 0.001), and FN1 (p = 0.004) in PC was related to poor prognosis (Figures 6(a)–6(d)).

4. Discussion

Population aging is becoming a major concern, and the rise in incidence of PC [14] has increased the burden on our economy. More emphasis has been laid on improving our understanding of PC pathogenesis and the quest for new treatment alternatives. RNA sequencing technology has been implemented to find DEGs between tumor and normal tissues. In spite of the large number of studies performed till now, there is inconsistency and substantial variation among results due to multiple factors.

In our study, we used the RRA method to minimize errors and biases among the 3 datasets. Finally, 350 upregulated and 243 downregulated robust genes were selected. Many of these genes have been reported to be oncogenic, such as gamma-aminobutyric acid type A receptor pi subunit (GABRP) [15], sulfatase 1 (SULF1) [16], and trefoil factor 1 (TFF1) [17]. Interestingly, some of these genes have also been documented as antioncogenes, such as aquaporin 8 (AQP8) [18], glycine N-methyltransferase (GNMT) [19], and zinc transporter ZIP5 (SLC39A5) [20]. In addition, other genes, including follistatin-like 1 (Fstl1), thymosin b10 (TMSB10), and G protein-coupled receptor (GPR87), were obtained. The function of these genes is still unclear, and further research is needed.

Prior studies have shown that TAMs promote tumor occurrence and proliferation and induce immunosuppression [21]. However, the mechanism is still unclear, warranting
Figure 2: Continued.
Figure 2: Heat map of DEGs in pancreatic cancer and normal tissue samples. (a) Heat map of GSE101448, (b) heat map of GSE15471, (c) heat map of GSE62452, and (d) heat map of 20 upregulated and downregulated robust DEGs. The value represented log₂ fold change (FC), and the positivity or negativity of the values represented up- or downregulation of genes, which were represented by red or green. Red represents a higher expression level, while green represents a lower expression level. DEGs: differentially expressed genes.
Figure 3: Continued.
further research. As antigen-presenting cells, dendritic cells can activate T cells and exert antitumor effects. Dendritic cells exert a vital function in the initial stages of tumor immunity activation [22]. DC maturation is necessary to provide costimulatory signals to T cells, but while resting DCs occur within tumors, it is often insufficient to induce potent immunity, particularly in light of suppressive mechanisms within tumors [23]. Also, Bindea et al. [24], Quail and Joyce [7], and Fridman et al. [25] reported that tumor microenvironment is closely related to the tumorigenesis and tumor progression, as well as resistance to immunotherapy. Based on the cancer-immune cycle theory, antigen-presenting cells capture and process antigens released by cancer cells, and T cell activation exerts an important function in the antitumor process. We may infer that a change in the tumor microenvironment could be related to tumor pathogenesis and immune escape for PC, but this requires further research for substantiation.

To further clarify the functional role of these robust DEGs, we conducted enrichment analyses. GO annotation showed that these DEGs were closely associated with the ECM. Indeed, as we all know, abnormal ECM attachment is an important step in tumorigenesis. The ECM also exerts a vital function in regulating tissue development and homeostasis, and its dysregulation promotes tumor progression [26].

The result of KEGG revealed that abnormal amino acid metabolism and signaling pathways are involved in the pathogenesis of PC. Altogether, these results provide new insights for further studies.

In the present study, we also created a PPI network using the STRING database. One key module was identified using the MCODE plugin. Finally, 4 hub genes, including FN1, MSLN, PLAU, and VCAN, were screened, and survival analysis based on hub gene expression was performed with clinical information from TCGA database.

FN1, which can promote the production of stromal components [27], is also involved in cell proliferation and migration [28, 29]. Fibronectin 1 (FN1) has been suggested to be associated with the occurrence of various tumors [30–32]. PC is characterized by abundant tumor stroma fibrosis. However, the exact role of FN1 in the pathogenesis of PC remains blurred. Previously, Han et al. found statistically significant improved survival rates in gastric cancer patients with low FN1 expression [33]. This study result is similar to our findings. We found that FN1 expression in PC tumor tissues was higher, compared with nontumor tissues, and high FN1 expression correlated with a worse prognosis \((p = 0.004)\). In addition, higher macrophage infiltration was found in PC tumor tissue compared to normal tissue. The underlying reason may be that the shedding of TAM produces extracellular vesicles (FN1 is one of the main components), reducing pancreatic tumor cell sensitivity to chemotherapy drugs through the ERK pathway [34]. In addition, studies have found that FN1 protein can promote the proliferation of PC cells [35]. High FN1 expression has also been correlated to larger tumor diameter, worse TNM stage, or even more advanced AJCC stage [27].

MSLN was first discovered on the surface of mesothelial cells in 1992 [36]. In subsequent studies, it was found that MSLN may be involved in cell adhesion and differentiation, to name a few [37]. In addition, high MSLN RNA expression correlated with poor prognosis in patients with solid tumors, such as breast cancers [38], ovarian cancers [39], and cholangiocarcinoma [40]. These reports are consistent with our findings. In our study, high mesothelin levels were expressed in PC tissues and high MSLN expression was associated with
Figure 4: Immune cell infiltration profiling in pancreatic cancer and normal tissue samples. (a) Bar plot. (b) Heat map. (c) Violin plot.
Figure 5: PPI network of DEGs and selection of hub genes from 7 algorithms including MNC, degree, EPC, bottleneck, eccentricity, closeness, and betweenness. (a) PPI network. (b) The key module. (c) Hub genes were selected by the intersection of the top 50 genes. DEGs: differentially expressed genes. PPI: protein-protein interaction.
Figure 6: Continued.
a poor prognosis. MSLN is overexpressed in some solid tumors and underexpressed in normal tissues, which makes MSLN a potential therapeutic target gene. Excitingly, multicentric clinical trials have already proposed the hypothesis that MSLN could be an important target for immunotherapy [41–43].

Herein, we also found significantly higher PLAU expression levels in PC tissues, which correlated with poor prognosis. PLAU gene can promote the digestion of ECM components. It has been suggested that protein digestion can promote pancreatic ductal metaplasia, one of the causes of PC [44]. PLAU protein can also promote tumor occurrence, tumor cell proliferation, and invasiveness [45]. In addition, inhibiting PLAU expression can inhibit tumorigenesis and reduce resistance to gemcitabine [46].

The VCAN protein, as an important ECM component, is closely related to cell adhesion and angiogenesis [47, 48]. Studies have documented the role of VCAN in promoting tumorigenesis, tumor cell proliferation, and distant metastasis [49]. High expression levels of VCAN have also been reported in ovarian, liver, and colon cancer [50–52]. However, to the best of our knowledge, no attempt has been made to explore the role of VCAN in PC. Our study found higher expression levels of VCAN in PC tissues than in
normal tissues, which also correlated with a poor prognosis. It has been reported in the literature that VCAN promotes proliferation and invasion by activating the EGFR and NF-κB pathways [53]; however, its role in PC needs more in-depth analysis.

Our study faces some limitations. Further in vivo and in vitro experiments are needed to confirm the significance of the 4 hub genes in PC.

5. Conclusions
The integrated transcriptomic analysis was used to provide new insights into PC pathogenesis. We used the RRA method to merge multiple datasets and used the CIBERSORT algorithm to estimate immune cells’ infiltration. Enrichment analysis showed that the DEGs were associated with the occurrence and prognosis of PC. Four hub genes, including FN1, MSLN, PLA2U, and VCAN, may be considered as novel biomarkers of PC.

Abbreviations
PC: Pancreatic cancer
DEGs: Differentially expressed genes
RRA: Robust rank aggregation
PPI: Protein-protein interaction
TAM: Tumor-associated macrophages
ECM: Extracellular matrix
FN1: Fibronectin 1
MSLN: Mesothelin
PLAU: Plasminogen activator, urokinase
VCAN: Versican.

Data Availability
The datasets supporting the conclusion of this article are included within the article.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
Manjiang Li and Wei Ding wrote the article. Yuxu Wang and Yongbiao Ma processed the data analysis. Li Lin participated in its design. Wei Ding designed the study and reviewed the article.

Acknowledgments
We thank the Department of Hepatobiliary & Pancreatic Surgery, Weifang People’s Hospital.

Supplementary Materials
Supplementary 1. Supplementary Table S1: the 564 robust DEGs.
Supplementary 2. Supplementary Table S2: GO enrichment analysis of the 564 robust DEGs.

Supplementary 3. Supplementary Table S3: KEGG enrichment analysis of the 564 robust DEGs.

References
[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] R. Dumont, F. Puleo, J. Collignon et al., “A single center experience in resectable pancreatic ductal adenocarcinoma - the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update,” Acta Gastroenterologica Belgica, vol. 80, no. 4, pp. 451–461, 2017.
[3] K. J. Labori, M. H. Katz, C. W. Tzeng et al., “Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - a population-based cohort study,” Acta Oncologica, vol. 55, no. 3, pp. 265–277, 2016.
[4] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2017,” CA: a Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017.
[5] Z. Deng, J. Wang, B. Xu et al., “Mining TCGA database for tumor microenvironment-related genes of prognostic value in hepatocellular carcinoma,” BioMed Research International, vol. 2019, Article ID 2408348, 12 pages, 2019.
[6] J. Wang, G. Zhang, Y. Sui et al., “CD52 is a prognostic biomarker and associated with tumor microenvironment in breast cancer,” Frontiers in Genetics, vol. 11, article 578002, 2020.
[7] D. F. Quail and J. A. Joyce, “Microenvironmental regulation of tumor progression and metastasis,” Nature Medicine, vol. 19, no. 11, pp. 1423–1437, 2013.
[8] M. Binnewies, E. W. Roberts, K. Kersten et al., “Understanding the tumor immune microenvironment (TIME) for effective therapy,” Nature Medicine, vol. 24, no. 5, pp. 541–550, 2018.
[9] D. Zeng, M. Li, R. Zhou et al., “Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures,” Cancer Immunology Research, vol. 7, no. 5, pp. 737–750, 2019.
[10] B. Chen, M. S. Khodadoust, C. L. Liu, A. M. Newman, and A. A. Alizadeh, “Profiling tumor infiltrating immune cells with CIBERSORT,” Methods in Molecular Biology, vol. 1711, pp. 243–259, 2018.
[11] D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.
[12] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.
[13] C. H. Chin, S. H. Chen, H. H. Wu, C. W. Ho, M. T. Ko, and C. Y. Lin, “cytoHubba: identifying hub objects and subnetworks from complex interactome,” BMC Systems Biology, vol. 8, Suppl 4, p. S11, 2014.
[14] L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman, and L. M. Matrisian, “Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver,
and pancreas cancers in the United States,” Cancer Research, vol. 74, no. 11, pp. 2913–2921, 2014.

[15] S. H. Jiang, L. L. Zhu, M. Zhang et al., “GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+signalling in a GABA-independent manner,” Gut, vol. 68, no. 11, pp. 1994–2006, 2019.

[16] Y. Lyu, Y. Cheng, B. Wang, L. Chen, and S. Zhao, “Silfaketase I expression in pancreatic cancer and its correlation with clinicopathological features and postoperative prognosis,” Cancer Biomarkers, vol. 22, no. 4, pp. 701–707, 2018.

[17] T. Arumugam, W. Brandt, V. Ramachandran et al., “Trofofa factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis,” Pancreas, vol. 40, no. 6, pp. 815–822, 2011.

[18] Q. Wu, Z. F. Yang, K. J. Wang et al., “AQP8 inhibits colorectal cancer growth and metastasis by down-regulating PI3K/AKT signalling and PCDH7 expression,” American Journal of Cancer Research, vol. 8, no. 2, pp. 266–279, 2018.

[19] C. H. Yen, Y. T. Lin, H. L. Chen, S. Y. Chen, and Y. M. A. Chen, “The multi-functional roles of GNMT in toxicology and cancer,” Toxicology and Applied Pharmacology, vol. 266, no. 1, pp. 67–75, 2013.

[20] J. Jin, Z. Li, J. Liu, Y. Wu, X. Gao, and Y. He, “Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression,” Oncology Reports, vol. 34, no. 3, pp. 1431–1439, 2015.

[21] J. Kim and J. S. Bae, “Tumor-associated macrophages and neutrophils in tumor microenvironment,” Mediators of Inflammation, vol. 2016, Article ID 6058147, 11 pages, 2016.

[22] S. Abediankenari, G. Janbabaei Mollae, M. Ghasemi, J. Jin, Z. Li, J. Liu, Y. Wu, X. Gao, and Y. He, “Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression,” Oncology Reports, vol. 34, no. 3, pp. 1431–1439, 2015.

[23] C. H. Yen, Y. T. Lin, H. L. Chen, S. Y. Chen, and Y. M. A. Chen, “The multi-functional roles of GNMT in toxicology and cancer,” Toxicology and Applied Pharmacology, vol. 266, no. 1, pp. 67–75, 2013.

[24] J. Jin, Z. Li, J. Liu, Y. Wu, X. Gao, and Y. He, “Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression,” Oncology Reports, vol. 34, no. 3, pp. 1431–1439, 2015.

[25] C. H. Yen, Y. T. Lin, H. L. Chen, S. Y. Chen, and Y. M. A. Chen, “The multi-functional roles of GNMT in toxicology and cancer,” Toxicology and Applied Pharmacology, vol. 266, no. 1, pp. 67–75, 2013.

[26] J. Jin, Z. Li, J. Liu, Y. Wu, X. Gao, and Y. He, “Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression,” Oncology Reports, vol. 34, no. 3, pp. 1431–1439, 2015.

[27] J. Kim and J. S. Bae, “Tumor-associated macrophages and neutrophils in tumor microenvironment,” Mediators of Inflammation, vol. 2016, Article ID 6058147, 11 pages, 2016.

[28] S. Abediankenari, G. Janbabaei Mollae, M. Ghasemi, J. Jin, Z. Li, J. Liu, Y. Wu, X. Gao, and Y. He, “Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression,” Oncology Reports, vol. 34, no. 3, pp. 1431–1439, 2015.

[29] C. H. Yen, Y. T. Lin, H. L. Chen, S. Y. Chen, and Y. M. A. Chen, “The multi-functional roles of GNMT in toxicology and cancer,” Toxicology and Applied Pharmacology, vol. 266, no. 1, pp. 67–75, 2013.

[30] M. Sponziello, F. Rosignolo, M. Celano et al., “Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells,” Molecular and Cellular Endocrinology, vol. 431, pp. 123–132, 2016.

[31] L. J. Ma, S. W. Lee, L. C. Lin et al., “Fibronectin overexpression is associated with latent membrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma,” Tumour Biology, vol. 35, no. 2, pp. 1703–1712, 2014.

[32] C. Y. Yen, C. Y. Huang, M. F. Hou et al., “Evaluating the performance of fibronectin 1 (FN1), integrin αβ1 (ITGA4), syndecan-2 (SDC2), and glycoprotein CD44 as the potential biomarkers of oral squamous cell carcinoma (OSCC),” Biomarkers, vol. 18, no. 1, pp. 63–72, 2013.

[33] C. Han, L. Jin, X. Ma, Q. Hao, H. Lin, and Z. Zhang, “Identification of the hub genes RUNX2 and FN1 in gastric cancer,” Open Medicine, vol. 15, no. 1, pp. 403–412, 2020.

[34] C. P. R. Xavier, I. Castro, H. R. Cair et al., “Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine,” Cancer Letters, vol. 501, pp. 210–223, 2021.

[35] H. Miyamoto, T. Murakami, K. Tsuchida, H. Sugino, H. Miyake, and S. Tashiro, “Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins,” Pancreas, vol. 28, no. 1, pp. 38–44, 2004.

[36] K. Chang, L. H. Pai, J. K. Batra, I. Pastan, and M. C. Wilkingham, “Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium,” Cancer Research, vol. 52, no. 1, pp. 181–186, 1992.

[37] A. Rump, Y. Morikawa, M. Tanaka et al., “Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion*,” The Journal of Biological Chemistry, vol. 279, no. 10, pp. 9190–9198, 2004.

[38] Y. Wang, L. Wang, D. Li, H. Wang, and Q. Chen, “Mesothelin promotes invasion and metastasis in breast cancer cells,” The Journal of International Medical Research, vol. 40, no. 6, pp. 2109–2116, 2012.

[39] D. J. O’Shanessy, E. B. Somers, L. M. Palmer et al., “Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4,” Journal of Ovarian Research, vol. 6, no. 1, p. 29, 2013.

[40] L. Yu, M. Feng, H. Kim et al., “Mesothelin as a potential therapeutic target in human cholangiocarcinoma,” Journal of Cancer, vol. 1, pp. 141–149, 2010.

[41] R. Hassan, A. Thomas, C. Alewine, D. T. le, E. M. Jaffee, and I. Pastan, “Mesothelin immunotherapy for cancer: ready for prime time?,” Journal of Clinical Oncology, vol. 34, no. 34, pp. 4171–4179, 2016.

[42] X. Y. Zhao, B. Subramanyam, N. Sarapa, S. Golfer, and H. Dinter, “Novel antibody therapeutics targeting mesothelin in solid tumors,” Clinical Cancer Drugs, vol. 3, no. 2, pp. 76–86, 2016.

[43] M. R. Mancuso and J. W. Neal, “Novel systemic therapy against malignant pleural mesothelioma,” Translational Lung Cancer Research, vol. 6, no. 3, pp. 295–314, 2017.

[44] A. V. Pinho, L. Chantrill, and I. Rooman, “Chronic pancreatitis: a path to pancreatic cancer,” Cancer Letters, vol. 345, no. 2, pp. 203–209, 2014.
14 Disease Markers

[45] Q. Chen, D. Yu, Y. Zhao, J. Qiu, Y. Xie, and M. Tao, “Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis,” Journal of Cellular Biochemistry, vol. 120, no. 12, pp. 19496–19508, 2019.

[46] S. Asuthkar, V. Stepanova, T. Lebedeva et al., “Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer,” Molecular Biology of the Cell, vol. 24, no. 17, pp. 2620–2632, 2013.

[47] I. J. Edwards, “Proteoglycans in prostate cancer,” Nature Reviews. Urology, vol. 9, no. 4, pp. 196–206, 2012.

[48] S. Chida, H. Okayama, M. Noda et al., “Stromal VCAN expression as a potential prognostic biomarker for disease recurrence in stage II-III colon cancer,” Carcinogenesis, vol. 37, no. 9, pp. 878–887, 2016.

[49] K. Fujii, M. B. Karpova, K. Asagoe, O. Georgiev, R. Dummer, and M. Urosevic-Maiwald, “Versican upregulation in Sezary cells alters growth, motility and resistance to chemotherapy,” Leukemia, vol. 29, no. 10, pp. 2024–2032, 2015.

[50] A. V. Suhovskih, S. V. Aidagulova, V. I. Kashuba, and E. V. Grigorieva, “Proteoglycans as potential microenvironmental biomarkers for colon cancer,” Cell and Tissue Research, vol. 361, no. 3, pp. 833–844, 2015.

[51] S. Ghosh, L. Albitar, R. LeBaron et al., “Up-regulation of stromal versican expression in advanced stage serous ovarian cancer,” Gynecologic Oncology, vol. 119, no. 1, pp. 114–120, 2010.

[52] W. Naboulsi, D. A. Megger, T. Bracht et al., “Quantitative tissue proteomics analysis reveals versican as potential biomarker for early-stage hepatocellular carcinoma,” Journal of Proteome Research, vol. 15, no. 1, pp. 38–47, 2016.

[53] T. L. Yeung, C. S. Leung, K. K. Wong et al., “TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment,” Cancer Research, vol. 73, no. 16, pp. 5016–5028, 2013.